Where does Tianjin Asymchem Pharmaceuticals Co., Ltd. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Tianjin Asymchem Pharmaceuticals Co., Ltd. ranks #30,416 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Tianjin Asymchem Pharmaceuticals Co., Ltd. hold?

Tianjin Asymchem Pharmaceuticals Co., Ltd. holds 9 US utility patents granted between 2016 and 2023, spanning 10 technology areas.

What is Tianjin Asymchem Pharmaceuticals Co., Ltd.'s Innovation Score?

Tianjin Asymchem Pharmaceuticals Co., Ltd. has an Innovation Score of 28.6 out of 100 (28th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Tianjin Asymchem Pharmaceuticals Co., Ltd. focus on?

Tianjin Asymchem Pharmaceuticals Co., Ltd.'s top technology area is C07D (Heterocyclic Compounds) with 5 patents. Grants appear in 10 CPC subclasses total.

Is Tianjin Asymchem Pharmaceuticals Co., Ltd.'s patent grant rate increasing or decreasing?

Tianjin Asymchem Pharmaceuticals Co., Ltd.'s recent grant velocity is -50% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Tianjin Asymchem Pharmaceuticals Co., Ltd.'s patents?

Tianjin Asymchem Pharmaceuticals Co., Ltd.'s patents average 10.2 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Tianjin Asymchem Pharmaceuticals Co., Ltd. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Tianjin Asymchem Pharmaceuticals Co., Ltd.

USPTO PatentsView assignee record - 9 granted patents across 10 technology areas, recorded in grant years 2016–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Tianjin ranks #30,416 of 49,997 tracked US assignees by granted-patent volume, with 9 patents across 10 technology areas.

#30,416
of 49,997 US assignees by volume: 28th percentile
by Innovation Score (28.6/100): 10.2
avg claims per patent: -50%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R30416 · Foreign Corporation #30,416 · 9 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-PAR · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 9 grants
MID-PACK #30,416/49,997
PHOTO-FINISH Thorium Power
CPC-FOCUS C07D · 10 areas
INNOV-THIN 28.6/100
CLAIMS-PAR 10.2 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -50% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Thorium Power, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Tianjin Asymchem… · this assignee

29
3D Lighting… · lowest

7

What this shows Tianjin's Innovation Score is 28.6/100 (28th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Tianjin's grants concentrate

Tianjin Asymchem Pharmaceuticals Co., Ltd. is a focused PatentsView assignee: 10 CPC subclasses with 55.6% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2018 (4 grants) versus a trough of 1 in 2020. By volume, Tianjin sits between Thorium Power, Inc. and Tmaxtibero Co., Ltd..

Tianjin's three-year grant acceleration

Tianjin Asymchem Pharmaceuticals Co., Ltd. shows 1 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Thorium Power

9
Thorne Intellectu…

9
Three Smith Group

9
Thuasne

9
Tianjin Tianchuan…

9
Tinavi Medical

9
TLI

9
Tmaxtibero

9
Tianjin Asymchem… ◀

9

What this shows Tianjin holds 9 patents at rank #30,336, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Tianjin

By rank, the assignees closest to #30,336 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Tianjin's primary technology class.

Tianjin's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

29 28th percentile higher than 28% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

Tianjin Asymchem Pharmaceuticals Co., Ltd. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	2	22.2%
2018	4	44.4%
2020	1	11.1%
2021	1	11.1%
2023	1	11.1%

Which technologies does Tianjin Asymchem Pharmaceuticals Co., Ltd. patent most?

C07D - Heterocyclic Compounds 5

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 5

C12Y - Enzymes 4

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 4

C07C - Acyclic OR Carbocyclic Compounds 3

C12R - Indexing Scheme Associated With Subclasses C12c - C12q, Relating TO Microorganisms 2

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 1

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 1

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 1

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 1

Top 10 of 10 technology areas

Where it ranks

Overall rank by patents

#30,416

of 49,997 tracked assignees

Innovation Score

28.6 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Tianjin Asymchem Pharmaceuticals Co., Ltd.'s patent record in context - here's where to go next.

Tianjin Asymchem Pharmaceuticals Co., Ltd.'s lead technology class is C07D (Heterocyclic Compounds), 55.6% of its portfolio - see every assignee active in that class. Explore C07D
Ranked #30,416 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Tianjin Asymchem Pharmaceuticals Co., Ltd. against Thorium Power, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 28.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.